Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group AG    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
Delayed Quote. Delayed Swiss Exchange - 12/02 11:30:50 am
552.2 CHF   -0.14%
10:17aGLOBAL MARKETS LIVE: A flurry of acquisitions
01:55aLONZA : to Create Around 200 Jobs at Swiss Site
DJ
01:17aLONZA : boosts Swiss antibody drug conjugate business
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Lonza launches sale of $3.5 billion specialty chemicals unit: sources

09/30/2020 | 09:20am EST
FILE PHOTO: Swiss pharmaceutical group Lonza's world’s largest dedicated cell and gene therapy facility in Houston

Swiss contract drug maker Lonza is launching the sale of its Lonza Specialty Ingredients (LSI) unit, people close to the matter told Reuters on Wednesday, adding it could be worth 3-3.5 billion Swiss francs ($3.25-3.79 billion).

The sources said UBS is expected to send out information packages on LSI to peers such as Lanxess or Clariant as well as to private equity groups in October.

LSI has annual earnings before interest, tax, depreciation and amortisation of about 300 million Swiss Francs ($323 million) and may be valued at 10-12 times that in a potential deal, they said.

The Basel-based company, which announced the sale plans in July, was not available for comment, while UBS declined to comment.

LSI is divided into two units, one making microbial controls for paints, hygiene, personal care and wood treatment, and a specialty chemicals services business offering contract manufacturing to clients.

The division traces Lonza's industrial roots, which go back more than a century to when it made synthetic fertilisers.

In the first half of 2020, LSI's revenue decreased by 5% to 819 million Swiss Francs, while core EBITDA dropped slightly to 161 million.

Sales of products used in hygiene and home & personal care have increased during the COVID-19 pandemic, as has demand for vitamin b3 in feed applications. However, sales of products used in wood protection, oil and gas, crop protection and the composite materials business dropped.

After bulking up its main pharma business with a $5.5-billion takeover of U.S.-based drug capsule maker Capsugel in 2017, Lonza unloaded assets including its 1,200-employee water treatment and residential swimming pool care business last year to streamline activities.

($1 = 0.9233 Swiss francs)

By Arno Schuetze and Oliver Hirt


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
CLARIANT AG -0.69% 18.085 Delayed Quote.-15.69%
LANXESS AG -1.22% 58.48 Delayed Quote.-1.04%
LONZA GROUP AG -0.14% 552.2 Delayed Quote.56.57%
All news about LONZA GROUP AG
10:17aGLOBAL MARKETS LIVE: A flurry of acquisitions
01:55aLONZA : to Create Around 200 Jobs at Swiss Site
DJ
01:17aLONZA : boosts Swiss antibody drug conjugate business
RE
01:03aLONZA : Announces Customer-Dedicated Suites for Commercialization of Bioconjugat..
PU
12/01LONZA : Expands Development and Manufacturing Capabilities at Bend Site
AQ
11/30Moderna files for U.S. vaccine authorization, will seek EU nod
RE
11/30LONZA : Expands Development and Manufacturing Capabilities at Bend (OR) Site
PU
11/19LONZA : and Be The Match BioTherapies partner to expand Vein-to-Vein Cell and Ge..
PU
11/19LONZA : Expands Highly Potent Drug Product Development and Manufacturing Capabil..
AQ
11/17MODERNA : Lonza Congratulates Moderna on Interim Phase 3 Clinical Trial Data
AQ
More news
Financials
Sales 2020 6 165 M 6 878 M 6 878 M
Net income 2020 851 M 949 M 949 M
Net Debt 2020 2 833 M 3 161 M 3 161 M
P/E ratio 2020 47,4x
Yield 2020 0,53%
Capitalization 41 022 M 45 782 M 45 768 M
EV / Sales 2020 7,11x
EV / Sales 2021 6,51x
Nbr of Employees 15 913
Free-Float 99,6%
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 598,74 CHF
Last Close Price 553,00 CHF
Spread / Highest target 39,9%
Spread / Average Target 8,27%
Spread / Lowest Target -25,9%
EPS Revisions
Managers
NameTitle
Pierre-Alain Ruffieux Chief Executive Officer
Albert M. Baehny Chairman
Rodolfo Savitzky Chief Financial Officer
Werner J. Bauer Independent Director
Barbara May Richmond No-Executive Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP AG56.57%45 596
MODERNA, INC.620.91%55 799
CELLTRION, INC.90.06%41 539
IQVIA HOLDINGS INC.10.82%32 829
SEAGEN INC.55.27%31 988
IMMUNOMEDICS, INC.315.22%20 324